SCHEMBL6371489

SCHEMBL6371489

Cn1c(=O)c(Nc2ccc(NC(=O)c3ccco3)cc2)nc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGM P11217 10/20 1.00
▸ RAB9A P51151 5/20 0.56
▸ NPC1 O15118 4/20 0.56
▸ TP53 P04637 5/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ MAPT P10636 3/20 0.56
▸ KDM4E B2RXH2 3/20 0.56
▸ HTT P42858 2/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ GAA P10253 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ TSHR P16473 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ GFER P55789 1/20 0.54
▸ PKM P14618 1/20 0.53
▸ RXFP1 Q9HBX9 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6372041 0.84 PYGM (1.00) PYGMTP53SMN1; SMN2MAPTKDM4E
SCHEMBL5545707 0.83 PYGM (0.71) PYGMRAB9ANPC1TP53SMN1; SMN2
SCHEMBL6371759 0.82 PYGM (1.00) PYGMTP53SMN1; SMN2MAPTKDM4E
SCHEMBL14470661 0.80 PYGM (0.69) PYGMSMN1; SMN2KDM4EALDH1A1GAA
SCHEMBL6369652 0.80 PYGM (0.66) PYGMRAB9ANPC1TP53SMN1; SMN2
SCHEMBL5550430 0.79 PYGM (1.00) PYGM
SCHEMBL6371208 0.79 PYGM (0.65) PYGMRAB9ANPC1TP53SMN1; SMN2
SCHEMBL5547089 0.78 PYGM (0.69) PYGMRAB9ANPC1TP53SMN1; SMN2
SCHEMBL5545650 0.78 PYGM (0.66) PYGMRAB9ANPC1TP53SMN1; SMN2
SCHEMBL5550260 0.78 PYGM (0.68) PYGMRAB9ANPC1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1711184-B1 (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY JANSSEN PHARMACEUTICA NV (BE) 2007-07-18 — — EP disclosed
US-20050148586-A1 Quinoxalinones JANSSEN PHARMACEUTICA, N.V. (BE) 2005-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148586-A1 Quinoxalinones SLC5A2, GPR119, GLS2 PYGM 271/4885RAB9A 1238/4885NPC1 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback